

### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

Abdayem 1



Section 1. Identifying Inform	ation	
1. Given Name (First Name) Pamela	2. Surname (Last Name) Abdayem	3. Date 12-April-2020
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name David Planchard
5. Manuscript Title Oncogene Addiction and Immune Escap	oe: Friends or Foes?	
6. Manuscript Identifying Number (if you kn ATM-20-3036(E2020040291-31605792-2		
Section 2. The Work Under Co	onsideration for Public	ation
	but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,
Section 3. Relevant financial a	activities outside the s	ubmitted work.
of compensation) with entities as descri clicking the "Add +" box. You should rep	bed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount e one line for each entity; add as many lines as you need by e <b>present during the 36 months prior to publication</b> .
Are there any relevant conflicts of intere If yes, please fill out the appropriate info		
Name of Entity	Grant? Personal Nor	o-Financial Other? Comments
Pierre Fabre		✓ Travel expenses
Roche		✓ Travel expenses
Section 4. Intellectual Proper	ty Patents & Copyrig	hts
Do you have any patents, whether plans	ned, pending or issued, br	oadly relevant to the work? Yes V No

Abdayem 2



Section 5. Polationships not sovered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Abdayem reports non-financial support from Pierre Fabre, non-financial support from Roche, outside the submitted work; .

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Abdayem 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your



Section 1. Identifying Information							
1. Given Name (First Name) David	2. Surname (Last N	lame)		3. Date 12-April-2020			
4. Are you the corresponding author?	✓ Yes No	)					
5. Manuscript Title Oncogene Addiction and Immune Escap	oe: Friends or Foes	?					
6. Manuscript Identifying Number (if you kno ATM-20-3036(E2020040291-31605792-2							
Section 2. The Work Under Co	nsideration for	Publication					
Did you or your institution <b>at any time</b> receivany aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of intere	but not limited to g				tc.) for		
Section 3. Relevant financial a	activities outsid	e the submitted	work.				
Place a check in the appropriate boxes ir of compensation) with entities as descril clicking the "Add +" box. You should rep	bed in the instruct	ions. Use one line f	or each entit	y; add as many lines as you nee	d by		
Are there any relevant conflicts of intere If yes, please fill out the appropriate info		No					
Name of Entity	Grant? Person		Other?	Comments			
AstraZeneca		<b>✓</b>	<b>✓</b> Cli	nical Trials research			
Bristol-Myers Squibb			<b>✓</b> Cli	nical Trials research			
Boehringer Ingelheim			<b>✓</b> Cli	nical Trials research			
Celgene							
Daiichi Sankyo			<b>✓</b> Cli	nical Trials research			
Eli Lilly			<b>✓</b> Cli	nical Trials research			
Merck			<b>✓</b> Cli	nical Trials research			
Novartis		<b>✓</b>	<b>✓</b> Cli	nical Trials research			



Name of Entity	Grant?	Personal		Other?	Comments
		Fees?	Support		
Pfizer		<b>✓</b>	<b>✓</b>	✓	Clinical Trials research
Prime Oncology		$\checkmark$	$\checkmark$		
Peer CME		<b>✓</b>			
Roche		$\checkmark$	<b>✓</b>	<b>✓</b>	Clinical Trials research
Medimmun				<b>✓</b>	Clinical Trials research
Sanofi-Aventis				<b>✓</b>	Clinical Trials research
Taiho pharma				<b>✓</b>	Clinical Trials research
Novocure				<b>√</b>	Clinical Trials research
Do you have any patents, whether place Section 5. Relationships no			ed, broadly releva	nt to the	work? ☐ Yes 🗸 No
Are there other relationships or activit potentially influencing, what you wro				influence	d, or that give the appearance of
Yes, the following relationships/co	onditions/cir	cumstance	es are present (ex	olain belo	ow):
✓ No other relationships/conditions,	/circumstan	ces that pre	esent a potential	conflict o	finterest
At the time of manuscript acceptance On occasion, journals may ask authors					•



Section 6.

**Disclosure Statement** 

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Planchard reports personal fees, non-financial support and other from AstraZeneca, personal fees and other from Bristol-Myers Squibb, personal fees and other from Boehringer Ingelheim, personal fees from Celgene, personal fees and other from Daiichi Sankyo, personal fees and other from Eli Lilly, personal fees and other from Merck, personal fees, non-financial support and other from Novartis, personal fees, non-financial support from Prime Oncology, personal fees from Peer CME, personal fees, non-financial support and other from Roche, other from Medimmun, other from Sanofi-Aventis, other from Taiho pharma, other from Novocure, outside the submitted work;

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.